此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Dural Sac Area-Guided Spinal Anesthesia Dosing for TURP

2026年8月26日 更新者:Ezgi Budak Ozyalcın、Istanbul University

Clinical Effects of Individualized Spinal Anesthesia Dosing Based on Ultrasound-Measured Dural Sac Cross-Sectional Area in Patients Undergoing Transurethral Resection of the Prostate: A Prospective, Randomized Controlled Trial

This randomized controlled study will evaluate whether individualizing the dose of spinal anesthesia according to the ultrasound-derived dural sac cross-sectional area (DSCSA) can improve hemodynamic stability in patients undergoing transurethral resection of the prostate (TURP).

Participants aged 40 years or older will be randomly assigned to one of two groups. In the individualized-dose group, the anteroposterior diameter of the dural sac will be measured by ultrasound at the L3-L4 level, and DSCSA will be calculated from this measurement. The dose of intrathecal bupivacaine will then be individualized according to the calculated DSCSA. In the control group, participants will receive a fixed dose of intrathecal bupivacaine. Both groups will also receive intrathecal fentanyl.

The main outcome is the incidence of intraoperative hypotension. The study will also evaluate the number of hypotensive episodes, minimum mean arterial pressure, vasopressor and atropine requirements, sensory and motor block characteristics, respiratory monitoring parameters, cerebral oxygenation, and adverse events.

The study aims to determine whether a DSCSA-guided dosing strategy can reduce excessive spinal block and improve hemodynamic stability while maintaining effective spinal anesthesia.

研究概览

详细说明

This prospective, randomized controlled study compares two routinely used approaches to determining the intrathecal bupivacaine dose for spinal anesthesia in patients undergoing transurethral resection of the prostate (TURP). No new drug, new indication, or experimental treatment will be introduced. Both dosing approaches are currently used in routine clinical practice; the study will prospectively and randomly compare their clinical effects.

Participants will be randomly assigned to either a dural sac cross-sectional area (DSCSA)-guided individualized dosing group or a fixed-dose control group.

Before spinal anesthesia, the anteroposterior diameter of the dural sac will be measured by ultrasound at the L3-L4 intervertebral level. DSCSA will be calculated using the formula A = π × (D/2)².

In the individualized-dose group, a DSCSA of 150 mm² will be used as the reference value corresponding to 10 mg of intrathecal bupivacaine. The bupivacaine dose will be adjusted proportionally according to the participant's calculated DSCSA and limited to a minimum of 6 mg and a maximum of 12.5 mg. Fentanyl 25 micrograms will be added intrathecally.

In the fixed-dose group, participants will receive 10 mg (2 mL of 0.5%) intrathecal bupivacaine together with fentanyl 25 micrograms.

Spinal anesthesia will be performed at the L3-L4 intervertebral space using a 27-gauge Quincke needle. Standard intraoperative monitoring will be performed according to the study protocol. Sensory and motor block characteristics and hemodynamic variables will be recorded prospectively for comparison between the two dosing strategies.

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Male participants aged 40 years or older
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Scheduled to undergo transurethral resection of the prostate (TURP) for prostate cancer

Exclusion Criteria:

  • Refusal of spinal anesthesia
  • Local infection or wound at the planned puncture site
  • Current anticoagulant therapy
  • Neurological disease, including multiple sclerosis, myelopathy, or peripheral neuropathy
  • Known allergy to any of the study medications
  • Inability to maintain the required position during ultrasound measurement or spinal puncture

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:DSCSA-Guided Individualized Dose
The dural sac cross-sectional area (DSCSA) will be estimated from the ultrasound-measured anteroposterior dural sac diameter at the L3-L4 level. The intrathecal bupivacaine dose will be individualized according to the DSCSA, using 150 mm² as the reference area corresponding to 10 mg bupivacaine. The calculated bupivacaine dose will be limited to 6-12.5 mg. Fentanyl 25 micrograms will also be administered intrathecally.
The dural sac cross-sectional area (DSCSA) is calculated from the ultrasound-measured anteroposterior dural sac diameter at the L3-L4 level. The intrathecal bupivacaine dose is individualized according to DSCSA.
Hyperbaric bupivacaine is administered intrathecally in both study groups. In the DSCSA-guided group, the dose is individualized according to DSCSA, using 150 mm² as the reference corresponding to 10 mg, with a permitted dose range of 6 to 12.5 mg. In the fixed-dose group, 10 mg (2 mL of 0.5% bupivacaine) is administered.
Fentanyl 25 micrograms is administered intrathecally together with bupivacaine in both study groups.
有源比较器:Fixed Dose
Participants will receive a fixed intrathecal dose of 10 mg (2 mL of 0.5%) bupivacaine together with fentanyl 25 micrograms.
Hyperbaric bupivacaine is administered intrathecally in both study groups. In the DSCSA-guided group, the dose is individualized according to DSCSA, using 150 mm² as the reference corresponding to 10 mg, with a permitted dose range of 6 to 12.5 mg. In the fixed-dose group, 10 mg (2 mL of 0.5% bupivacaine) is administered.
Fentanyl 25 micrograms is administered intrathecally together with bupivacaine in both study groups.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of Intraoperative Hypotension
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Intraoperative hypotension is defined as a decrease in mean arterial pressure (MAP) of ≥20% from baseline or an MAP <65 mmHg. Participants meeting either criterion at least once during surgery will be classified as having intraoperative hypotension. The outcome will be reported as the percentage of participants with intraoperative hypotension.
During surgery (from completion of spinal anesthesia until the end of surgery)

次要结果测量

结果测量
措施说明
大体时间
Number of Intraoperative Hypotension Episodes
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Number of intraoperative hypotension episodes recorded for each participant. Hypotension is defined as a decrease in mean arterial pressure (MAP) of ≥20% from baseline or an MAP <65 mmHg.
During surgery (from completion of spinal anesthesia until the end of surgery)
Minimum Intraoperative Mean Arterial Pressure
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Lowest mean arterial pressure (MAP), measured in mmHg, recorded during the intraoperative period.
During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of Participants With a ≥30% Decrease in Mean Arterial Pressure
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of participants experiencing at least one decrease in mean arterial pressure (MAP) of ≥30% from baseline during surgery.
During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of Participants Requiring Ephedrine
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of participants receiving at least one intravenous dose of ephedrine for treatment of intraoperative hypotension.
During surgery (from completion of spinal anesthesia until the end of surgery)
Total Ephedrine Dose
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Total intravenous ephedrine dose, measured in milligrams (mg), administered to each participant during surgery.
During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of Participants Requiring Atropine
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of participants receiving intravenous atropine for treatment of intraoperative bradycardia.
During surgery (from completion of spinal anesthesia until the end of surgery)
Total Atropine Dose
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Total intravenous atropine dose, measured in milligrams (mg), administered to each participant during surgery.
During surgery (from completion of spinal anesthesia until the end of surgery)
Maximum Sensory Block Level
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Highest cephalad sensory block level achieved after spinal anesthesia, assessed by the pin-prick test and recorded as the corresponding dermatomal level.
During surgery (from completion of spinal anesthesia until the end of surgery)
Time to Achieve T10 Sensory Block
大体时间:Up to 30 minutes after spinal anesthesia
Time, measured in minutes, from completion of intrathecal injection to achievement of a T10 sensory block, assessed using the pin-prick test.
Up to 30 minutes after spinal anesthesia
Time to Two-Dermatome Sensory Regression
大体时间:From maximum sensory block until two-dermatome regression, assessed up to 3 hours after spinal anesthesia
Time, measured in minutes, from the maximum sensory block level to regression of the sensory block by two dermatomes, assessed using the pin-prick test.
From maximum sensory block until two-dermatome regression, assessed up to 3 hours after spinal anesthesia
Time to Recovery to Modified Bromage Score 0
大体时间:From completion of spinal anesthesia until recovery to Modified Bromage score 0, assessed up to 3 hours after spinal anesthesia
Time, measured in minutes, from completion of intrathecal injection until recovery to a Modified Bromage score of 0, indicating complete recovery of lower-extremity motor function.
From completion of spinal anesthesia until recovery to Modified Bromage score 0, assessed up to 3 hours after spinal anesthesia
Number of Integrated Pulmonary Index ≤4 Episodes
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Number of episodes in which the Integrated Pulmonary Index (IPI) is ≤4. The IPI is a composite score ranging from 1 to 10 based on end-tidal carbon dioxide, respiratory rate, oxygen saturation, and pulse rate; lower scores indicate greater respiratory compromise.
During surgery (from completion of spinal anesthesia until the end of surgery)
Incidence of Adverse Events
大体时间:During surgery (from completion of spinal anesthesia until the end of surgery)
Percentage of participants experiencing at least one adverse event recorded during the intraoperative study period.
During surgery (from completion of spinal anesthesia until the end of surgery)

其他结果措施

结果测量
措施说明
大体时间
Mean Left Regional Cerebral Oxygen Saturation During the First 60 Minutes
大体时间:During the first 60 minutes after spinal anesthesia
Mean left regional cerebral oxygen saturation (rSO₂), measured continuously by frontal near-infrared spectroscopy (NIRS) during the first 60 minutes after spinal anesthesia. The outcome will be reported as the mean rSO₂ value.
During the first 60 minutes after spinal anesthesia
Minimum Regional Cerebral Oxygen Saturation
大体时间:During the first 60 minutes after spinal anesthesia
Lowest regional cerebral oxygen saturation (rSO₂) value recorded by frontal near-infrared spectroscopy (NIRS) during the first 60 minutes after spinal anesthesia.
During the first 60 minutes after spinal anesthesia
Maximum Relative Decrease in Regional Cerebral Oxygen Saturation
大体时间:During the first 60 minutes after spinal anesthesia
Maximum relative decrease in regional cerebral oxygen saturation (ΔrSO₂max) from the baseline value during the first 60 minutes after spinal anesthesia, measured by frontal near-infrared spectroscopy (NIRS).
During the first 60 minutes after spinal anesthesia

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ezgi Budak Özyalçın, MD、Istanbul University - Cerrahpasa

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月24日

初级完成 (估计的)

2026年11月24日

研究完成 (估计的)

2026年12月10日

研究注册日期

首次提交

2026年8月23日

首先提交符合 QC 标准的

2026年8月26日

首次发布 (实际的)

2026年8月31日

研究记录更新

最后更新发布 (实际的)

2026年8月31日

上次提交的符合 QC 标准的更新

2026年8月26日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅